Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of Zanubrutinib in B-cell Malignancies
jRCT2011240032Active, not recruiting
- Sponsor
- BeOne Medicines
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Open-label, single-arm trial of zanubrutinib in B-cell malignancy, sponsored by BeOne Medicines. Primary endpoint: Incidence of treatment-emergent adverse events and serious adverse events. Started Oct 2024; status: active, not recruiting.
02
Drugs
zanubrutinib
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on jRCT2011240032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240032.